BioSpace News Archive

Researchers at Carnegie Mellon University (CMU) have developed a low-cost sensor that can identify COVID-19 antibodies in approximately 10 seconds. The novel sensor is based on a special structure of tiny gold electrodes that are 3D printed using the Optomec Aerosol Jet process. The technology would allow clinicians to instantly and accura

The study, now published in the JMIR academic journal, examines the predictive accuracy of Diabits and the correlation between daily use of the app and blood glucose control

Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce it has raised A$27,950,000 (before costs) in a placement to institutional, professional and sophisticated investors that will result in 21,500,000 full paid ordinary shares being issued at A$1.30 per share (Placement).

New Study at Montefiore Aims to Identify Who Can be Cared for at Home and Who Would Benefit from Hospital Care

Jack Wang, Ph.D., is the newest member to join to Allevion Therapeutics’ board of directors.

Cleft lip and palate (clefts) are the most common birth difference of the face and mouth and impact the development of the mouth, gums, and palate.

Ardigen, a company applying Artificial Intelligence to Precision Medicine, has signed a grant agreement with the National Centre for Research and Development for the funding of a novel technology that will revolutionize the development of TCR-based therapies in immuno-oncology.

Neurelis, Inc., announced today that it will be investigating the safety and pharmacokinetics of the company’s lead product, VALTOCO® (diazepam nasal spray), in children with epilepsy aged two to five.

Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy’s Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.

Accenture (NYSE: ACN) today announced that it has built a data and analytics approach to manage and derive insights from pediatric acute myeloid leukemia (AML) genomic data.